FISH‐ing for answers: Can genomic arrays add to our understanding of disease biology in low‐risk chronic lymphocytic leukaemia?

Abstract

Patients with chronic lymphocytic leukaemia can have an indolent or aggressive clinical course. Current guidelines recommend performing immunoglobin heavy chain testing, four‐colour probe fluorescence in situ hybridization testing and mutational analysis for TP53 mutations as part of routine prognostic testing to determine if high‐risk genomic features are present. Rigolin et al. demonstrate that genomic microarray testing can identify high‐risk genomic features in patients deemed low risk by current testing standards and is independently associated with shorter time to first treatment in their cohort.Commentary on: Rigolin et al. Additional lesions identified by genomic microarrays are associated with an inferior outcome in low‐risk chronic lymphocytic leukaemia patients. Br J Haematol 2023;202:953–959.